Abstract: The present invention concerns nanoparticle formulations suitable for the delivery of one or more therapeutic agents the formulations comprising: a cationic cholesterol derivative; a neutral phospholipid; cholesterol or a neutral cholesterol derivative; and a saturated fatty acid PEGylated neutral derivative of phosphatidylethanolamine or phosphatidylcholine.
| # | Name | Date |
|---|---|---|
| 1 | 777-KOLNP-2015.pdf | 2015-03-25 |
| 2 | PCT IB 304.pdf | 2015-03-28 |
| 3 | FORM 5.pdf | 2015-03-28 |
| 4 | FORM 3.pdf | 2015-03-28 |
| 5 | FORM 2 & Complete Specification.pdf | 2015-03-28 |
| 6 | DRAWINGS AS FILED.jpg | 2015-03-28 |
| 7 | 777-KOLNP-2015-Power of Attorney-180515.pdf | 2015-09-01 |
| 8 | 777-KOLNP-2015-Correspondence-180515.pdf | 2015-09-01 |
| 9 | Petition Under Rule 138 [18-09-2015(online)].pdf | 2015-09-18 |
| 10 | 777-KOLNP-2015-(24-09-2015)-CORRESPONDENCE.pdf | 2015-09-24 |
| 11 | 777-KOLNP-2015-(24-09-2015)-ANNEXURE TO FORM 3.pdf | 2015-09-24 |
| 12 | 777-KOLNP-2015-(07-10-2015)-OTHERS.pdf | 2015-10-07 |
| 13 | 777-KOLNP-2015-(07-10-2015)-FORM-1.pdf | 2015-10-07 |
| 14 | 777-KOLNP-2015-(07-10-2015)-CORRESPONDENCE.pdf | 2015-10-07 |
| 15 | Form 13 [13-10-2015(online)].pdf | 2015-10-13 |
| 16 | 777-KOLNP-2015-(16-10-2015)-OTHERS.pdf | 2015-10-16 |
| 17 | 777-KOLNP-2015-(16-10-2015)-FORM-1.pdf | 2015-10-16 |
| 18 | 777-KOLNP-2015-(16-10-2015)-CORRESPONDENCE.pdf | 2015-10-16 |
| 19 | 777-KOLNP-2015-Power of Attorney-170915.pdf | 2015-11-23 |
| 20 | 777-KOLNP-2015-Correspondence-170915.pdf | 2015-11-23 |
| 21 | Form 18 [15-07-2016(online)].pdf | 2016-07-15 |
| 22 | 777-KOLNP-2015-FER.pdf | 2018-07-30 |
| 23 | 777-KOLNP-2015-AbandonedLetter.pdf | 2019-02-14 |
| 1 | SEARCHREPORT_27-07-2018.pdf |